PTCT PTC THERAPEUTICS, INC.
FY2025 10-K
PTC THERAPEUTICS, INC. (PTCT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
- • Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
Management Discussion & Analysis
- • Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
- • Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
Risk Factors
- • Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
- • Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
Financial SummaryXBRL
Revenue
$1.7B
Net Income
$683M
Operating Margin
50.1%
Net Margin
39.4%
ROE
-332.5%
Total Assets
$2.9B
EPS (Diluted)
$7.78
Operating Cash Flow
$711M
Source: XBRL data from PTC THERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on PTC THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.